Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Spain

Spain

In Spain, the Neoplasm Treatment market is anticipated to witness a substantial increase in revenue, with projections indicating a rise to €4.69bn euros by 2024.
This growth is expected to continue at a steady pace, with a compound annual growth rate (CAGR) of 2.86% from 2024 to 2029, resulting in a market volume of €5.40bn euros by the end of the forecast period.
When compared globally, United States is expected to generate the highest revenue in this market, with a projected amount of €83.11bn euros in 2024.
Spain's neoplasm treatment market is seeing a rise in the adoption of innovative immunotherapies for cancer patients.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.